Neumora Therapeutics, Inc. Common Stock
NMRA
NASDAQ·Healthcare·Biotechnology·Mkt cap $242.7M
$1.31
▼ -2.96%
P/E
-1.07
Mkt Cap
$242.7M
52-Wk Range
$0.83–$3.65
52-Week Range
$0.83 - $3.65
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 21.1% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary kappa opioid receptor antagonist technology platform
- Novel mechanism of action for depression with reduced side effect profile potential
- Diversified pipeline targeting multiple high-prevalence neurological conditions
- Strategic focus on unmet medical needs in underserved therapeutic areas
Bear Case
1 risk
- High volatility (beta 2.7). Larger-than-normal price swings expected.
Growth
Stable outlook
Phase 3 clinical trial completion and potential FDA approval of navacaprant for depression
Value
Deep value opportunity - significant discount to sector peers
Momentum
Weak
-19.1% over 3m
Quality
Loss-making
Below average quality
Dividend
None
No dividend
Smart-money signal
Who's buying NMRA right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 4, 2026
AUG 14, 2026
Reported EPS of -$0.23 vs -$0.24 consensus (+4.2% surprise).
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+4.2%
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$0
$0
$0
$0
$0
$0
Margins · last 8Q
No margin history available.
Wall Street consensus
4 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: HC Wainwright · Jul 28, 2026
vs Industry
How NMRA stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.